SP1 and neoplasm: Given that Sp1 expression can be suppressed by the clinically available drug Bortezomib, an ubiquitin-proteasome inhibitor, in tumor cells27, our findings imply a rationale for a clinical trial of combination between imatinib and Bortezomib.